SCHEMBL145559

SCHEMBL145559

C/C=C(/[C]=O)c1cccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
PLK1 P53350 1/20 0.49
MMP3 P08254 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
CDC25B P30305 2/20 0.44
PTPN1 P18031 1/20 0.44
PTK2B Q14289 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
HPGD P15428 3/20 0.42
POLB P06746 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
GMNN O75496 2/20 0.42
LMNA P02545 2/20 0.42
MAPK1 P28482 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144064 0.83 NR4A1 (0.44) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL2106556 0.80 NR4A1 (0.42) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL6027698 0.76 NR4A1 (0.52) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL6027696 0.76 NR4A1 (0.52) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL144246 0.75 NR4A1 (0.61) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL143957 0.73 PTK2B (0.55) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL2538243 0.73 NR4A1 (0.59) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL3317975 0.72 NR4A1 (0.57) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL9806354 0.72 NR4A1 (0.52) NR4A1NR4A2NR4A3PLK1MMP3
SCHEMBL9410290 0.72 NR4A1 (0.57) NR4A1NR4A2NR4A3PLK1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 677 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7375081-B2 Therapeutic combination of a pneumocandin derivative and an antifungal agent ASTELLAS PHARMA INC. (JP) 2008-05-20 US claimed
US-6875740-B1 Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-05 US claimed
US-20240084308-A1 FIBROTIC TREATMENT MONASH UNIVERSITY (AU) 2024-03-14 US disclosed
US-20240034845-A1 POLYMER PARTICLES QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) 2024-02-01 US disclosed
EP-3384549-B1 SODIUM-ION ELECTROLYTE COMPOSITION UNIV DEAKIN (AU) 2024-01-17 EP disclosed
US-11834663-B2 Fibrotic treatment MONASH UNIVERSITY (AU) 2023-12-05 US disclosed
US-20230348674-A1 HYDROGELS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2023-11-02 US disclosed
CN-113939544-B non-core-shell polymer particles 悉尼大学 2023-08-22 CN disclosed
CN-116615468-A Polymer particles 昆士兰科技大学 2023-08-18 CN disclosed
EP-4225811-A1 POLYMER PARTICLES Queensland University Of Technology (AU) 2023-08-16 EP disclosed
WO-2023121483-A1 IMMUNOSTIMULATORY COMPOSITIONS VICTORIA LINK LIMITED (NZ) 2023-06-29 WO disclosed
WO-1992018483-A1 QUINOLINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-10-29 WO disclosed
US-5155101-A Tricyclic compounds FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1992-10-13 US disclosed
EP-0498069-A2 New use of peptide derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-08-12 EP disclosed
WO-1992012154-A1 IMIDAZOTRIAZINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-07-23 WO disclosed
WO-1992003438-A1 TRICYCLIC BENZODIAZEPINE DERIVATES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-03-05 WO disclosed
WO-1992002513-A1 HETEROCYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-02-20 WO disclosed
US-4981847-A Tricyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-01 US disclosed
EP-0360079-A1 Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-03-28 EP disclosed
EP-0336230-A2 Cyclic peptide antagonists of Substance P and Substance K FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-10-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834663-B2 Fibrotic treatment MMP1, ENPEP, RNPEP NR4A1 4148/4885NR4A2 3058/4885NR4A3 2826/4885
US-20230348674-A1 HYDROGELS PHYKPL, TST, PHOSPHO1 NR4A1 4576/4885NR4A2 3957/4885NR4A3 3494/4885
US-20240084308-A1 FIBROTIC TREATMENT MMP1, ENPEP, RNPEP NR4A1 4148/4885NR4A2 3058/4885NR4A3 2826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.